Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma
NCT07180992 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25
Last updated 2025-11-18
Summary
Tumoral micro-environment in malignant haematological diseases, notably in multiple myeloma, is active on plasma cells survival and proliferation. Monocytosis and monocytes typing are described in multiple myeloma response as factors on proliferation and cell death evasion. CART cells have improved multiple myeloma care in last 5 years, nethertheless, early relapse occur and we must identify predictor factors of better response. The aim of this study is to analyze basic level and phenotyping of monocytes before and after CART cells infusion and study their impact on multiple myeloma response
Conditions
- Multiple Myeloma
- Monocytes
- CART Cells
Sponsors & Collaborators
-
Centre Hospitalier Universitaire, Amiens
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-07-16
- Primary Completion
- 2028-09-30
- Completion
- 2028-09-30
Countries
- France
Study Locations
More Related Trials
-
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
NCT04155749 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
MYeloma Resistance And Clonal Evolution
NCT03807128 ·Status: RECRUITING
-
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
NCT01775553 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
NCT05431608 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma
NCT01792102 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Context of Carfilzomib Nominative Expanded Access and Compassionate Use
NCT04811508 ·Status: COMPLETED
-
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
NCT05396885 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma
NCT02597062 ·Status: COMPLETED ·Phase: PHASE2
-
Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients
NCT06888856 ·Status: NOT_YET_RECRUITING
-
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
NCT06577025 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06297226 ·Status: RECRUITING ·Phase: PHASE2
-
Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients
NCT04379817 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
NCT02302495 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
NCT06066346 ·Status: RECRUITING ·Phase: PHASE2
-
Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
NCT01410500 ·Status: APPROVED_FOR_MARKETING
-
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT03361748 ·Status: COMPLETED ·Phase: PHASE2
-
Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma
NCT05208086 ·Status: ACTIVE_NOT_RECRUITING
-
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
NCT02561962 ·Status: COMPLETED ·Phase: PHASE1
-
Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma
NCT02800954 ·Status: COMPLETED ·Phase: NA
-
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
NCT00721734 ·Status: COMPLETED ·Phase: PHASE2
-
Multiple Myeloma Minimal Residual Disease
NCT02627261 ·Status: COMPLETED
-
A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib
NCT00689507 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
NCT00530816 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma
NCT04499339 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
NCT03111992 ·Status: COMPLETED ·Phase: PHASE1